ScaleReady’s Post

Tired of high material costs in cell therapy manufacturing? There's a better way. Learn how switching to Wilson Wolf Manufacturing, LLC G-Rex bioreactors and peripheral blood can streamline your process and reduce expenses. See the proof! https://lnkd.in/efQDr2Eb #celltherapy #processoptimization

Our highly anticipated cell therapy webinar is just one week away, so secure your spot before it's too late ⏳ https://ter.li/9bwzoc Get ready to explore how allogeneic cell therapies are making waves with scalable and innovative alternatives to traditional autologous treatments. Here’s a sneak peek: 💸 Total deal value involving allogeneic cell therapies in 2023 was $981 million, but this year we’ve already surpassed that investment! 🔬 130 allogeneic trials have their end dates this year, providing a wealth of new data and insights. 🧪 Over 440 allogeneic trials are currently recruiting participants. Find out more about these promising developments. Our expert panel will dive deep into these exciting advancements. Don’t miss the chance to stay ahead of the curve and unlock the potential of cutting-edge allogeneic solutions in oncology and beyond. #CellTherapy #Allogeneic #AllogeneicTherapies #MarketInsights Hanson Wade Intelligence

5 billion T cells from 1L of media? This is possible. See how the Wilson Wolf Manufacturing, LLC G-Rex bioreactor achieved exceptional output in cell therapy production. Download the case study to learn more: https://lnkd.in/efQDr2Eb #celltherapy #efficiency #G-Rex

🗣️ Cellistic recently hosted a webinar as part of the Cell&Gene program at the Outsourced Pharma Capacity virtual event. We discussed some of the main challenges of allogeneic cell therapy: ❓How to manufacture allogeneic treatments to accelerate their delivery to patients? ❓What are the obstacles? ❓How can new cell therapy technologies address them? Watch the #webinar recording here to gain some insights from #expert Stefan Braam about those questions & do not hesitate to reach out for a discussion! #Cellistic #AllogeneicCellTherapy #iPSCs

From cell therapies to treat solid tumors to a growing number of allogeneic cell therapies coming through the clinical pipeline, there is plenty to be excited about in the cell therapy space as we head into 2025. In this segment from “Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond,” our panelists Kevin Caldwell, Hamid Khoja, Ph.D., and Robert Williamson discuss promising innovations in the field and share what data and approvals they look forward to seeing in 2025. https://lnkd.in/eXTRR-Uc

Leveraging living human cells to fight disease has already proven to be incredibly powerful in hematological oncology and holds huge promise, e.g. in devastating autoimmune diseases. However, autologous cell therapies are difficult to make, and 7 years after the first approvals, only about 35,000 patients have been treated with all approved products combined. We need truly breakthrough innovations to bring such therapies to all patients in need. What if.. we build targeted platforms to better engineer cells directly in vivo - skipping ex vivo cell manufacturing alltogether?! Read my short viewpoint article summarizing my thoughts. https://lnkd.in/gnZGpzvB

#FlagshipFounded Mirai Bio President & COO Jens H. Vogel, Ph.D. describes current and future innovations that aim to realize the full potential of cell and gene therapies for the benefit of patients globally in this Cell & Gene Therapy Insights article: https://lnkd.in/eWxQRu-8

Mirai Bio President and COO, Jens H. Vogel, Ph.D. captures the scalability challenges facing #celltherapies in this Cell & Gene Therapy Insights article, exploring innovative solutions like in vivo engineering to expand patient access and streamline production.

CAR-T cell therapy holds immense promise, but traditional transfection methods can compromise cell health. In this application with Avectas , the health of Triple Knock-Out (KO) transfected T-cells was evaluated by measuring cell expansion and viability in a Gas Permeable Rapid Expansion G-Rex platform using different cell culture media and cytokine supplement. The app note explores: • Solupore®'s performance with Triple Knock-Out (KO) T cells • Consistent expansion across different culture media • High viability throughout the process Download the app note now to unlock the full potential of CAR-T therapies with G-Rex: https://lnkd.in/eN3-psyp #CARTTherapy #CellManufacturing #Solupore #NonViral #Transfection #Efficiency #Viability

Carcinomas account for ~90% of cancers. This is why the recent FDA approval of TIL therapy is changing the field of cell therapy. In this podcast, Jason Bock talks with Daniel Levine about this achievement and what is on the horizon with the brilliant next generation TILs in development and in the clinic. #biotech #celltherapy #TILtherapy #endcancer https://lnkd.in/et-A5hUe